EBD GmbH

  • Land: Schweiz

Nachricht vom 12.03.2019 | 12:00

EBD Group: BIO-Europe Spring(R) 2019 comes to Vienna in two weeks for 13th annual springtime biopharma conference

DGAP-News: EBD Group / Key word(s): Conference

12.03.2019 / 12:00
The issuer is solely responsible for the content of this announcement.


BIO-Europe Spring 2019(R) comes to Vienna in two weeks for 13th annual springtime biopharma conference

Carlsbad, CA and Vienna, Austria - March 12, 2019: On March 25-27, the thirteenth annual BIO-Europe Spring(R) international partnering conference will convene in Vienna, Austria, at the Messe Wien Exhibition and Congress Center. The event is expected to draw over 2,500 pharma and biotech executives seeking valuable partnerships and investment, who will participate in a projected 15,000+ one-to-one meetings during the three-day conference.

There is still time to sign up and request meetings with your best-fit partners. Click here to register before online registration closes on March 22.

The event is produced by EBD Group and hosted by LISAvienna, a joint life science platform operated by the Vienna Business Agency and Austria Wirtschaftsservice on behalf of the Austrian Federal Ministry for Digital and Economic Affairs and the City of Vienna.

The opening keynote plenary discussion, "Time to turn the ship: Exploring underserved therapeutic areas," on Monday, March 25, will feature speakers Michael Crowley, Head of BD for Pharma Research and Early Development at Roche Pharma Partnering; Cartier Esham, EVP for Emerging Companies, Biotechnology Innovation Organization (BIO); David Rossow, Founding Partner, Strategic Investment Fund at the Bill & Melinda Gates Foundation; Jonathan Wang, Senior VP and Head of BD at Zai Lab; and moderator Amy Schulman, Partner at Polaris Partners.

Monday afternoon features Business Development, Spotlight and Therapeutics tracks covering investing, Asia-Pacific trends, NASH, cell and gene therapies, oncology partnering, and more.

On Tuesday, there are sessions on digital medicine and European biotech, a plenary highlighting "A day in the life of experienced dealmakers," as well as a Startup Spotlight event sponsored by Eli Lilly and Company offering expert advice on fostering innovation, valuation, attracting partners, maximizing resources, and funding strategies, with presentations by a series of innovative early-stage biotech companies.

The Labiotech Refresh event on Wednesday covers the outlook for European biotech; in addition, there are several panels on microbiome therapeutics.

Large and midsize pharma, biotech, and academic organizations will present their innovations and technologies, and the exhibit hall will feature nearly 100 top-notch companies. Besides the 15,000+ one-to-one partnering meetings expected, informal networking opportunities abound at the evening receptions both at the venue and out on the town at the historic Vienna City Hall, the Hofburg Palace, and the Old World-style Gösserhalle.

Vienna is a biotech hub known for its thriving life science community where most of the top 20 multinational companies in biotech, pharma and medical devices have a presence, taking advantage of Austria's ideal geographical location at the heart of Europe.

For more information about BIO-Europe Spring and to register to attend the event, visit the BIO-Europe Spring website.

# # #

Additional links and information:

Follow BIO-Europe Spring 2019 on Twitter @EBDGroup (hashtag: #BIOEuropeSpring) or LinkedIn

About EBD Group
EBD Group's overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our seven landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE(R), that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.

Today our events (BIO-Europe(R), BIO-Europe Spring(R), BioPharm America(TM), Biotech Showcase(TM), China Showcase, Digital Medicine & Medtech Showcase, ChinaBio(R) Partnering Forum, Cell & Gene Connect, and BioEquity Europe) annually attract more than 12,000 senior life science executives who engage in over 48,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.

Tune into EBD Group's Partnering Insight for timely coverage of news that influences the business strategies of the life science industry. EBD Group is an Informa company. For more information please visit www.ebdgroup.com.


Media Contacts:

Raimund Gabriel
MC Services AG
+49 89 2102280
contact@mc-services.eu

Kari Bennett
EBD Group
+1 (760) 930-0500
kbennett@ebdgroup.com



12.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Anleihe im Fokus

Technologiespezialist Hörmann Industries begibt 50 Mio. Euro-Anleihe – Mindestzinssatz von 4,5% p.a.

Die Hörmann Industries GmbH begibt eine neue Unternehmensanleihe mit einem Volumen von bis zu 50 Millionen Euro. Die neue Anleihe der Technologiespezialisten aus Oberbayern (ISIN: NO0010851728 / WKN: A2TSCH) wird im sogenannten Nordic Bond-Format begeben und unterliegt norwegischem Recht.


ISIN: NO0010851728
Stückelung: 1.000 Euro
Zeichnungsmöglichkeit: Börse Frankfurt, über die Haus- oder Direktbank
Mindestzinssatz: 4,500 %
Zinssatz (Kupon) p.a.: Bekanntgabe spätestens nach Ende des Angebotszeitraums,voraussichtlich am 28. Mai 2019
Laufzeit: 5 Jahre

Interview im Fokus

„Das Globalmatix-Geschäft wird hochprofitabel“

Durchbruch für Globalmatix: Die Tochter der Softing AG hat mit dem Gewinn eines Großkunden einen wichtigen Meilenstein erreicht. „Wir sehen sehr gute Chancen, bei laufenden Ausschreibungen weitere Erfolge zu feiern“, zeigt sich Softing-CEO Dr. Trier optimistisch. Die hohe Skalierbarkeit soll Softing dem Ziel einer zweistelligen EBIT-Marge näherbringen. Die Prognose für 2019 sieht Dr. Trier angesichts des starken Auftragsbestands als konservativ.

Event im Fokus

m:access Fachkonferenz Immobilien
m:access Fachkonferenz Software/IT


04. Juni 2019: m:access Fachkonferenz Immobilien
05. Juni 2019: m:access Fachkonferenz Software/IT
Veranstaltungsort: Börse München
Mehr Informationen

Zur Veranstaltung können sich nur professionelle Investoren anmelden.

GBC-Fokusbox

Studie GBC Best of m:access I.2019: Weiter im Aufwind und mit starker Outperformance

Das Qualitätssegment m:access hat sich in den letzten Jahren fulminant entwickelt und ist auch 2018 weiter gewachsen. Zuletzt umfasste der m:access einen Rekordwert von 60 Unternehmen unterschiedlichster Branchen mit einer Gesamtmarktkapitalisierung von rund EUR 12 Mrd. Der von GBC berechnete m:access Index hat im Betrachtungszeitraum eine starke Outperformance gezeigt. Auch für die neue Top 15 Best-Of-Auswahl sind die Analysten wieder sehr positiv gestimmt. Die Studie steht kostenlos zum Download zur Verfügung.

News im Fokus

Vonovia SE: Vonovia beantragt Squeeze-out-Verfahren zum Erwerb der Minderheitenanteile an Victoria Park (News mit Zusatzmaterial)

24. Mai 2019, 09:05

Aktueller Webcast

ADO Properties S.A.

Dreimonats-
Investor Call
Q1 2019

22. Mai 2019

Aktuelle Research-Studie

curasan AG

Original-Research: curasan AG (von Montega AG): Halten

24. Mai 2019